Manus Funding: $500M Round Follows Beijing's Order 837 Shift

A deal unwound, a company refinanced

Manus, the AI agent startup whose sale to Meta was blocked by Beijing, has raised more than $500 million in its first funding round since the transaction was reversed. The round was co-led by Boyu Capital and IDG Capital, with existing shareholders Tencent, HSG and ZhenFund also participating. 23 The company did not disclose a post-money valuation. A Bloomberg report cited by CNBC indicated the round would put Manus at roughly $4 billion, double its earlier figure and ahead of every other Chinese AI agent company. 3

The fundraise matters beyond the headline number. It is the clearest market signal so far of how China's assertion of jurisdiction over offshore, Chinese-founded AI firms is changing who funds them and how they plan to exit. That assertion is now written into regulation.

How the Manus precedent was set

The sequence is short. Manus was built by a Chinese team, moved its place of incorporation to Singapore in June 2025, and agreed to be acquired by Meta for about $2 billion that December. 1 On April 27, 2026, China's National Development and Reform Commission (NDRC) issued a prohibition order directing Meta to unwind the completed deal. 1 Coverage framed the order as part of broader scrutiny of US investment in Chinese startups working on advanced AI. 2

NDRC's reasoning drew the most attention. The regulator looked past Manus's Singaporean shareholding structure and traced the technology, talent and intellectual property back to China. It concluded that core technology developed in China falls under Chinese jurisdiction regardless of where the company is incorporated. 1 Order 837, published after the case, turns that logic into a general rule rather than a one-off intervention. 1 Domestically incorporated Chinese companies carry the heaviest compliance load under the new framework, described as up to five layers of regulatory review and a high cost of exit. 1

Who wrote the checks, and who didn't

The round's makeup is arguably more revealing than its size. Benchmark, the Silicon Valley firm that led Manus's 2025 Series B, does not appear among the new investors. 4 US venture money has in effect been replaced by private equity firm Boyu, IDG, and returning Chinese backers. 4 That has been read as a sign that institutional US VCs are growing cautious about Chinese-origin AI startups now that offshore incorporation no longer shields a deal from Beijing. One analyst described the ruling as the end of "Singapore washing," the practice of redomiciling to sidestep Chinese oversight. 4

Not everyone reads the moment as a chill. Eurasia Group's China director, Dan Wang, told CNBC the raise shows the short-term fallout from the Meta case has been contained, and that investors are willing to back Manus as an independent company. 3 The two readings can both hold. Capital is clearly still available for Manus. It is coming from a narrower, more regionally aligned pool.

The exit map is redrawn

The financing fits a new path for the company. Manus has reportedly been preparing for a Hong Kong IPO, which suggests the round is better understood as pre-listing growth capital than as a conventional venture bet. 4 Reporting also points to plans for future growth that include a possible joint venture in China. 2 Both moves point Manus toward Chinese and Hong Kong markets rather than a US acquirer.

That is the practical effect of Order 837 as these sources describe it. Before the Manus case, a Chinese-founded AI team could plausibly treat a Singapore holding company as a route to a US strategic sale. After it, that route carries the risk of being reversed by a Chinese regulator even after closing. 1 Founders and investors now have to plan for Beijing's review as a structural feature of any cross-border deal.

What to watch

The Manus outcome is a relatively soft landing: a doubled valuation and a clear path to the public markets. It should not be read as a template for every affected company. Manus had strong domestic backers and enough momentum to attract capital quickly. Smaller Chinese-origin startups that relied on a US buyer as their most likely exit may find the new regime far more constraining.

The broader question is whether the change to who participates in these rounds proves lasting. If Benchmark's absence reflects a wider retreat, valuations for Chinese-founded AI companies may come to depend increasingly on Hong Kong listings and domestic strategic investors. Order 837 makes it likely that the line between "Chinese" and "offshore" AI startups is drawn by Beijing rather than by corporate filings in Singapore. Dealmakers will be pricing that in for some time.